Monte Rosa Therapeutics (GLUE) Return on Equity (2023 - 2025)
Monte Rosa Therapeutics (GLUE) has 3 years of Return on Equity data on record, last reported at 0.08% in Q3 2025.
- For Q3 2025, Return on Equity rose 64.0% year-over-year to 0.08%; the TTM value through Sep 2025 reached 0.08%, up 64.0%, while the annual FY2024 figure was 0.36%, N/A changed from the prior year.
- Return on Equity reached 0.08% in Q3 2025 per GLUE's latest filing, down from 0.09% in the prior quarter.
- Across five years, Return on Equity topped out at 0.09% in Q2 2025 and bottomed at 0.82% in Q1 2024.
- Average Return on Equity over 3 years is 0.37%, with a median of 0.45% recorded in 2024.
- Peak YoY movement for Return on Equity: skyrocketed 40bps in 2024, then soared 84bps in 2025.
- A 3-year view of Return on Equity shows it stood at 0.74% in 2023, then soared by 54bps to 0.34% in 2024, then soared by 124bps to 0.08% in 2025.
- Per Business Quant database, its latest 3 readings for Return on Equity were 0.08% in Q3 2025, 0.09% in Q2 2025, and 0.02% in Q1 2025.